A leader from the clinical data solutions firm explains how the challenges created by the pandemic have helped fuel creativity and innovation in studies.
In the drive to advance personalized medicine, researchers are increasingly turning to radiomics to assist in the discovery of new types of biomarkers.
The American Heart Association’s Heart of Communicating Science modules are designed to help experts break complex talk into easy-to-understand language.
William Gholston, with the Tampa Bay Buccaneers football team, is donating to the Moffitt Cancer Center to fund research into cancer treatment disparities.
California information technology and services company Syntegra and the National Institutes of Health (NIH) have signed a partnership to 'democratize access to the largest set of COVID-19 patient records': with the use of Syntegra's synthetic...
Sosei Heptares and PharmEnable will harness artificial intelligence-enabled technology and advanced chemistry to explore neurological disease solutions.
Exploring alternative uses for drugs tapped for other indications, can save considerable time and money in discovery, according to an expert from the CRO.
The drug delivery platform company is exploring the viability of remdesivir and other potential treatments for the virus using its DehydraTECH technology.
The two organizations will collaborate on development of synthetic arms for clinical studies, drawing from millions of patient records and trial subject.
A leader from the IQVIA company explains how the boom in the volume and quality of data, and advanced analysis, can speed and streamline drug development.
A partnership between Immunai and 10x Genomics will use artificial intelligence to create a map of the immune system to help accelerate drug development.
Sanofi has made a new five-year, $25m partnership agreement with the World Health Organization (WHO) to fight Neglected Topical Diseases (NTD); and eliminate sleeping sickness by 2030.
OSP's free Digital Advances in Clinical Trial webinar (on December 9) will feature experts discussing recent advancements in the rapidly evolving field.
The online DNA network has delved into self-reported data of more than 563,000 US adults to help identify genetic risk of infection and severe outcomes.
Health tech specialists GoodCell are working with the New York Blood Center to identify COVID-19 patients with elevated risk of adverse clinical outcomes.
The federal agency has offered updates, advice and action regarding the COVID-19 pandemic, helping life-sciences professionals stay on top of developments.
A leader from the drug research and development company discusses unique problems faced by COVID-19 patients with prior cancer and autoimmune diagnoses.
The company's Spectus and Percepta platforms offer features to help researchers meet challenges associated with working and collaborating in the pandemic.
Thermo Fisher Scientific will partner with AstraZeneca and the University of Nebraska Medical Center to advance biomarker discovery and characterization.
The drug discovery and pharma companies have extended their agreement to collaborate on development of new treatments for a range of therapeutic areas.
A leader from Iqvia will present an overview of artificial intelligence, machine learning and other \technology during this year’s CPhI Festival of Pharma.
Merck and Seattle Genetics have announced two strategic oncology collaborations: one to develop Seattle Genetics’ antibody-drug conjugate ladiratuzumab vedotin worldwide; and another to accelerate the global reach of Tukysa (tucatinib).
Innovative research by Tabula Rasa Healthcare uses simulation technology to analyze potential adverse drug events of potential therapies for the virus.
The pharma firm and health association plan to collaborate in order to help drive global action toward prevention and control of cardiovascular disease.
